**Table S3. Lack of HIV-1 and hepatitis C neutralization by B-CLL IgM paraproteins and the corresponding recombinant IgG1 mAbs**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **HIV-1 pseudoviruses tested (TZM-bl)** | | | | **HCV neutralization** | | |
| **mAb ID** | **B.SF162** | **B.BG1168** | **B.MN** | **MuLV** | **H77 (genotype 1a)** | |
| CLL246 IgM | - | - | - | - | - |
| CLL526 IgM | - | - | - | - | - |
| CLL698 IgM | - | - | - | - | - |
| CLL821 IgM | - | - | - | - | - |
| CLL1324 IgM | - | - | - | - | - |
| CLL1296 IgM | - | - | - | - | - |
| CLL246 IgG1 | - | - | - | - | nd |
| CLL526 IgG1 | - | - | - | - | nd |
| CLL698 IgG1 | - | - | - | - | nd |
| CLL821 IgG1 | - | - | - | - | nd |
| CLL1324 IgG1 | - | - | - | - | nd |

The B-CLL IgM paraproteins and the recombinant IgG1 mAbs were tested at 0.02 – 50 µg/ml in a standard TZM-bl assay. No detectable activity (< 50% neutralization) is indicated with “-“. The CLL1296 IgM was used as a negative control antibody. Nd, not determined.